More than 45 organizations, including the AHA, today encouraged members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974), which the panel is expected to consider next week. The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs,” the organizations said in a letter to committee leaders. “The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over 10 years. We sincerely thank you and your colleagues who have supported the CREATES Act, and we encourage all members of the Committee to vote in favor of the bill.” 

Headline
AHA Board Chair Marc Boom, M.D., took the stage July 13 to introduce AHA award winners and a town hall discussion on navigating the 2026 political…
Perspective
Public
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
The AHA provided a statement June 30 to the House Ways and Means Committee in advance of a markup July 1 where the committee will consider legislation that…
Headline
The House Appropriations Committee June 9 approved their version of the FY 2027 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
Rep. Randy Feenstra, R-Iowa, yesterday introduced a House version of the Rural Community Hospital Demonstration Program Reauthorization Act, a bill that would…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…